NHS National Framework for Transition products (Nilotinib and Ticagrelor)

A Contract Award Notice
by NHS ENGLAND

Source
Find a Tender
Type
Framework ()
Duration
not specified
Value
£22M
Sector
MISCELLANEOUS
Published
20 Aug 2025
Delivery
not specified
Deadline
n/a

Concepts

Location

Geochart for 1 buyers and 7 suppliers

1 buyer

7 suppliers

Description

Project title: NHS National Framework for Transition products (Nilotinib and Ticagrelor) commencing 1st September 2025 Offer reference number: CM/TNS/24/5721 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5721/01 - Nilotinib and Ticagrelor Lot 1 DCE/DNW/DNE: 01/09/2025 to 31/01/2027 (17 months) Lot 2 DLN/DLS/DSW: 01/09/2025 to 31/01/2027 (17 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

Award Detail

1 Zydus Pharmaceuticals (Bristol)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
2 Accord (Devon)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
3 Astrazeneca (London)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
4 Drreddys Laboratories (Cambridge)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
5 MSN Laboratories Europe (Hitchin)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
6 Novartis Pharmaceuticals (London)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.
7 Zentiva Pharma (London)
  • NHS National Framework for Transition products (Nilotinib and Ticagrelor)
  • Reference: 1
  • Value: £22,097,000 [share]
  • Awarded to group of suppliers.

CPV Codes

  • None found

Indicators

Other Information

Please note that the contract had erroneously been advertised as an open framework at the tender stage and should have been advertised as a standalone framework. Additional Unsuccessful supplier not listed due to technical error: Torrent Pharma (UK) Ltd ** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

Domains